ORCHARD THERAPEUTICS PLC.

In News

Charity bringing to EU market gene therapy spurned by pharma - BioWorld MedTech

BioWorld MedTech - Nov 14, 2025

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD - GlobeNewswire

GlobeNewswire - Dec 02, 2025

Orchard Therapeutics PLC (ORTX) Reports Q3 2023 Earnings and Announces Acquisition by Kyowa Kirin - Yahoo Finance

Yahoo Finance - Nov 13, 2023

Kyowa Kirin acquires Orchard Therapeutics for $477.6m - Pharmaceutical Technology

Pharmaceutical Technology - Jan 25, 2024

Why Orchard Therapeutics Stock Is Soaring Today - The Motley Fool

The Motley Fool - Aug 25, 2020

Orchard Therapeutics: A Reassessment (NASDAQ:ORTX) - Seeking Alpha

Seeking Alpha - Sep 18, 2023

GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics - GSK

GSK - Apr 12, 2018

Orchard sets out to sell world’s priciest gene therapy - BioPharma Dive

BioPharma Dive - Mar 20, 2024

Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin - Nasdaq

Nasdaq - Oct 06, 2023

Orchard to lose out on milestone payments as Pharming Group ends collab - The Business Journals

The Business Journals - May 08, 2024

Berns becomes chairman, CEO of Neumora - BioCentury

BioCentury - Feb 14, 2025

Orchard Therapeutics Appoints New Leadership - Contract Pharma

Contract Pharma - Sep 09, 2021

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment